AI-Powered Drug Discovery Market to Reach USD 9.2 Billion by 2035 as Drug Repurposing Captures 52% Share, North America Accounts for 45%-50% of Global Demand, and Exscientia, Insilico Medicine & Schrödinger Accelerate Generative AI-Driven Drug Developme

Wilmington, DE, USA, 11th May 2026 - According to MarketGenics Global Research, the global AI-powered drug discovery market is valued at USD 1 billion in 2025 and is projected to reach USD 9.2 billion by 2035, expanding at a CAGR of 24.6% during the forecast period (2025-2035).

The market is witnessing rapid expansion due to increasing pharmaceutical R&D costs, growing adoption of generative AI and predictive modeling technologies, rising demand for accelerated drug development timelines, expansion of cloud-based computational biology platforms, and increasing integration of machine learning algorithms into target identification, molecular design, and clinical trial optimization workflows.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables): https://marketgenics.co/reports/ai-powered-drug-discovery-market-96109

==============================
MARKET OVERVIEW - KEY STATISTICS
==============================

Drivers - Increasing Industry Imperatives Accelerating AI-Powered Drug Discovery Adoption

The AI-powered drug discovery market is experiencing accelerated growth because pharmaceutical and biotechnology companies are increasingly deploying artificial intelligence technologies to reduce R&D expenses, improve candidate success rates, accelerate molecular screening, and optimize target identification across complex therapeutic discovery pipelines.

Key Fact

AI-powered drug discovery platforms can reduce early-stage drug development timelines by up to 30%-40% while improving candidate selection accuracy, according to recent industry analyses.

Challenges - Data Quality, Regulatory and Integration Challenges

The deployment of AI-powered drug discovery systems continues facing barriers associated with fragmented datasets, evolving AI regulatory frameworks, integration complexity within existing R&D infrastructure, and limited interoperability between computational biology systems and traditional pharmaceutical research environments.

Regulatory Landscape

The AI-powered drug discovery market is shaped by evolving FDA, EMA, and global regulatory guidelines surrounding AI validation, clinical data usage, predictive modeling standards, and AI-generated drug development workflows.

==============================
EMERGING MARKET OPPORTUNITIES
==============================

Global Market Opportunity

~USD 8.2 Billion Total Forecast Opportunity by 2035

The global AI-powered drug discovery market is expected to create an incremental opportunity of nearly USD 8.2 billion by 2035, supported by rising deployment of generative AI models, cloud-based computational biology platforms, predictive toxicology systems, AI-enabled clinical trial optimization solutions, and multi-omics data analytics infrastructure.

Regional Opportunity Analysis

~North America Remains the Most Attractive Regional Opportunity During 2025-2035

North America continues dominating the global AI-powered drug discovery market due to advanced healthcare IT infrastructure, strong pharmaceutical and biotechnology ecosystem presence, high venture capital investments, and increasing collaboration between AI technology firms and pharmaceutical companies.

Get Sample Copy of the Report: https://marketgenics.co/download-report-sample/ai-powered-drug-discovery-market-96109

==============================
KEY FINDINGS OF THE AI-POWERED DRUG DISCOVERY MARKET REPORT
==============================

• Total forecast market opportunity expected to exceed USD 8.2 billion by 2035

• Drug repurposing segment accounts for approximately 52% of the global AI-powered drug discovery market share in 2025

• North America contributes nearly 45%-50% of total global market demand

• Top five companies account for more than 40% of total market share globally

• Generative AI, predictive modeling, and cloud-native computational biology platforms are transforming pharmaceutical R&D strategies

• Target identification, de novo drug design, predictive toxicology, and multi-omics analytics remain high-growth implementation areas

==============================
ANALYST VIEWPOINT
==============================

The global AI-powered drug discovery industry is transitioning beyond conventional pharmaceutical R&D workflows toward AI-native computational biology ecosystems optimized for predictive molecular modeling, accelerated target identification, generative chemistry development, clinical trial optimization, and scalable cloud-based biomedical research infrastructure.

Competitive positioning within the industry is increasingly defined by:

• generative AI and predictive modeling capability

• cloud-native computational biology infrastructure

• multi-omics data integration expertise

• accelerated molecular simulation capability

• AI-driven toxicity prediction systems

• pharmaceutical and biotech collaboration networks

==============================
SEGMENTAL INSIGHTS & GROWTH ANCHORS
==============================

Market Share by Application (2025)

• Drug Repurposing - ~52%

• Target Identification

• De Novo Drug Design

• Pharmacokinetics and ADMET Prediction

• Others

The drug repurposing segment dominates the global AI-powered drug discovery market due to increasing demand for reduced development timelines, lower R&D costs, improved candidate success rates, and rapid identification of therapeutic opportunities using AI-enabled predictive analytics and large-scale biomedical datasets.

North America dominates the global AI-powered drug discovery market, accounting for approximately 45%-50% of total market share in 2025, supported by strong pharmaceutical R&D infrastructure, increasing venture capital investments, growing AI adoption across life sciences, and strategic collaborations between pharmaceutical companies and AI technology providers.

Regional Share Analysis, 2025

• United States

• Canada

• Mexico

Key Technology Trends

North America continues leading the AI-powered drug discovery ecosystem due to increasing adoption of generative AI platforms, machine learning-driven predictive modeling systems, cloud-based computational biology infrastructure, and multi-omics analytics platforms supporting advanced pharmaceutical research.

==============================
COMPETITIVE LANDSCAPE & KEY PLAYERS
==============================

Global Company Market Share (2025)

• Exscientia plc

• Insilico Medicine, Inc.

• Schrödinger, Inc.

• Atomwise, Inc.

• Recursion Pharmaceuticals, Inc.

• Other Key Players

The global AI-powered drug discovery market remains moderately consolidated with the top five manufacturers controlling more than 40% of total market share in 2025. Exscientia plc maintains strong leadership through its generative AI-driven drug discovery platforms, predictive molecular design capabilities, cloud-native computational biology systems, and strategic pharmaceutical collaboration ecosystem supporting accelerated therapeutic development.

Exscientia plc

• Company Revenue: USD 25 Mn

• Headquarters: United Kingdom

• In 2025, Exscientia plc launched its Centaur AI platform featuring generative and predictive AI models for target identification, lead optimization, and compound design, enabling pharmaceutical and biotech companies to accelerate drug discovery workflows, reduce R&D costs, and improve candidate success rates.

Insilico Medicine, Inc.

• Company Revenue: USD 85.8 Mn

• Headquarters: United States

• Insilico Medicine, Inc. partnered with NVIDIA to integrate high-performance GPU computing with its AI-powered drug discovery platform, combining scalable computational infrastructure with advanced deep learning models to accelerate molecular design, target identification, and predictive toxicity analysis.

Other Key Companies Operating in the AI-Powered Drug Discovery Market Include:

• Atomwise, Inc.

• BenevolentAI Limited

• Berg LLC

• Exscientia plc

• BioXcel Therapeutics, Inc.

• Cyclica Inc.

• Deep Genomics Inc.

• Healx Limited

• Iktos S.A.

• Insilico Medicine, Inc.

• Insitro, Inc.

• Lantern Pharma Inc.

• Numerate, Inc.

• Valo Health, Inc.

• Recursion Pharmaceuticals, Inc.

• Schrödinger, Inc.

• Standigm Inc.

• Owkin, Inc.

• Verge Genomics, Inc.

• XtalPi Inc.

• Other Key Players

==============================
RECENT DEVELOPMENTS & INDUSTRY NEWS
==============================

• In August 2025, Scipher Medicine launched ClinicalTrialRank.com, an AI-powered platform designed to forecast clinical trial failures and improve early-stage investment and development decision-making for biopharmaceutical organizations.

• In September 2025, major pharmaceutical companies partnered with Eli Lilly and Superluminal Medicines in a USD 1.3 billion collaboration focused on AI-enabled structure-based drug discovery systems targeting cardiometabolic diseases and obesity therapies.

• In September 2025, Eli Lilly introduced TuneLab, an AI-powered predictive modeling platform designed to accelerate therapeutic discovery and reduce pharmaceutical development timelines.

• In October 2025, Nabla Bio expanded its AI-driven protein therapeutic design collaboration with Takeda Pharmaceutical to accelerate biologics development using advanced machine learning systems.

The industry is rapidly evolving toward generative AI-native pharmaceutical ecosystems, cloud-based computational biology platforms, predictive molecular simulation systems, AI-enhanced clinical trial optimization frameworks, and scalable biomedical analytics infrastructure supporting next-generation drug development.

==============================
AI-POWERED DRUG DISCOVERY MARKET SEGMENTATION
==============================

By Offering

• Software Platforms

• AI Algorithms and Models

• Cloud-Based Drug Discovery Platforms

• Data Analytics Platforms

• Services

By Technology

• Machine Learning (ML)

• Deep Learning

• Natural Language Processing (NLP)

• Computer Vision

• Reinforcement Learning

• Generative AI Models

• Others

By Drug Type

• Small Molecules

• Large Molecules / Biologics

• Gene Therapy-Based Drugs

• RNA-Based Therapeutics

• Others

By Discovery Stage

• Target Identification and Validation

• Hit Identification / Screening

• Hit-to-Lead Optimization

• Lead Optimization

• Preclinical Testing

• Others

By Therapeutic Area

• Oncology

• Neurology and Neurodegenerative Diseases

• Cardiovascular Diseases

• Infectious Diseases

• Metabolic Disorders

• Immunology and Autoimmune Diseases

• Respiratory Disorders

• Rare Diseases

• Others

By Deployment Mode

• Cloud-Based Platforms

• On-Premise Platforms

• Hybrid Deployment

By Data Type

• Genomics Data

• Proteomics Data

• Clinical Trial Data

• Chemical Structure Data

• Real-World Data (RWD)

• Others

By Application

• Target Identification

• Drug Repurposing

• De Novo Drug Design

• Virtual Screening

• Biomarker Discovery

• Toxicity Prediction

• Pharmacokinetics and ADMET Prediction

• Others

By End User

• Pharmaceutical Companies

• Biotechnology Companies

• Contract Research Organizations (CROs)

• Academic and Research Institutes

• Healthcare AI Startups

• Others

==============================
FUTURE OUTLOOK & STRATEGIC PERSPECTIVE
==============================

The global AI-powered drug discovery market is positioned for substantial long-term growth as pharmaceutical companies, biotechnology firms, cloud infrastructure providers, and AI technology organizations continue accelerating investments in generative AI platforms, predictive molecular analytics systems, cloud-native computational biology infrastructure, and AI-enhanced pharmaceutical research ecosystems.

North America is expected to remain the dominant growth engine due to strong pharmaceutical innovation infrastructure, robust venture capital investments, expanding pharma-tech collaboration networks, and increasing deployment of advanced AI systems across biomedical research and therapeutic development workflows.

BUY NOW: https://marketgenics.co/buy/ai-powered-drug-discovery-market-96109

Contact:

Mr. Debashish Roy

MarketGenics Global Research

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About MarketGenics

MarketGenics is a global market research and business advisory firm empowering decision-makers across startups, Fortune 500 companies, non-profit organizations, universities, and government institutions. The company delivers comprehensive market intelligence, industry analysis, and strategic insights across diverse sectors.

MarketGenics publishes detailed industry research reports combining granular quantitative analysis with expert insights on market trends, competitive landscapes, and emerging opportunities. These reports help organizations make informed strategic decisions, identify growth opportunities, and support sustainable business development.

In addition to research publications, MarketGenics supports organizations with strategic insights on product development, application modeling, market expansion strategies, and identifying niche growth opportunities.

This release was published on openPR.